title: Prostaglandin E2 production in astrocytes: regulation by cytokines, extracellular ATP, and oxidative agents.
abstract: Upregulation and activation of phospholipases A2 (PLA2) and cyclooxygenases (COX) leading to prostaglandin E2(PGE2) production have been implicated in a number of neurodegenerative diseases. In this study, we investigated PGE2 production in primary rat astrocytes in response to agents that activate PLA2 including pro-inflammatory cytokines (IL-1beta, TNFalpha and IFNgamma), the P2 nucleotide receptor agonist ATP, and oxidants (H2O2 and menadione). Exposure of astrocytes to cytokines resulted in a time-dependent increase in PGE2 production that was marked by increased expression of secretory sPLA2 and COX-2, but not COX-1 and cytosolic cPLA2. Although astrocytes responded to ATP or phorbol ester (PMA) with increased cPLA2 phosphorylation and arachidonic acid release, ATP or PMA only caused a small increase in levels of PGE2. However, when astrocytes were first treated with cytokines, further exposure to ATP or PMA, but not H2O2 or menadione, markedly increased PGE2 production. These results suggest that ATP release during neuronal excitation or injury can enhance the inflammatory effects of cytokines on PGE2 production and may contribute to chronic inflammation seen in Alzheimer's disease.
authors: Department of Biochemistry, University of Missouri, Columbia, MO 65212, USA.
authors: J
authors: J
authors: Xu
authors: M
authors: M
authors: Chalimoniuk
authors: Y
authors: Y
authors: Shu
authors: A
authors: A
authors: Simonyi
authors: A Y
authors: AY
authors: Sun
authors: F A
authors: FA
authors: Gonzalez
authors: G A
authors: GA
authors: Weisman
authors: W G
authors: WG
authors: Wood
authors: G Y
authors: GY
authors: Sun
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism*; D016207:Cytokines / Q000502:physiology*; D015232:Dinoprostone / Q000096:biosynthesis*; D005260:Female; D006861:Hydrogen Peroxide / Q000494:pharmacology; D007120:Immunochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000378:metabolism; D016877:Oxidants / Q000494:pharmacology*; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D058910:Purinergic P2 Receptor Agonists; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D024483:Vitamin K 3 / Q000494:pharmacology
chemical_list: D016207:Cytokines; D016877:Oxidants; D058910:Purinergic P2 Receptor Agonists; D012333:RNA, Messenger; D016718:Arachidonic Acid; D009569:Nitric Oxide; D024483:Vitamin K 3; D000255:Adenosine Triphosphate; D006861:Hydrogen Peroxide; D011451:Prostaglandin-Endoperoxide Synthases; D010741:Phospholipases A; D054467:Phospholipases A2; D015232:Dinoprostone